Basket | Login | Register

 
 
 
 

LO-MAPT (coming soon)

Phase III trials

Study Information

Name of the study

Prevention of cognitive decline in older adults with low Dha/Epa index in red blood cells

Study sponsor

University Hospital, Toulouse 

Disease

Subjective memory complaints or family history of Alzheimer's disease

Phase

Phase III

Information about the drug that will be tested in the study

Name of drug

Dietary supplement: Omega-3 treatment

Where and when will the study be conducted?

European countries involved in the trial

France

Estimated start date of recruitment

April 2018

Information for your doctor

Clinicaltrials.gov identifier

NCT03691519

Study contact information

Bruno Vellas - vellas.b@chu-toulouse.fr

Arnaud Lendrieuy - lendrieux.a@chu-toulouse.fr

Link to full text

https://clinicaltrials.gov/ct2/show/NCT03691519

An accessible easy read information on the LO-MAPT study will be available soon.

 

 
 

Last Updated: Friday 09 August 2019

 

 
 

Options